Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1055/a-1296-7935 http://scihub22266oqcxt.onion/10.1055/a-1296-7935 33176367!8043595!33176367     free     free     free       Drug+Res+(Stuttg) 2021 ; 71 (3): 166-170 Nephropedia Template TP {{tp|p=33176367|t=2021. Favipiravir and COVID-19: A Simplified Summary |pdf=|usr=}}{{33176367}} gab.com Text Favipiravir and COVID-19: A Simplified Summary JO: Drug Res (Stuttg) http://www.kidney.de/pget.php?&tw=1&pmid=33176367 #FOAvip A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan, China, at the end of 2019 and then spread rapidly all over the world. However, there are no specific antiviral therapies for COVID-19, using the agents which approved or in development for other viral infections is one of the potentially quickest ways to find treatment for this new viral infection. Favipiravir is an effective agent that acts as a nucleotide analog that selectively inhibits the viral RNA dependent RNA polymerase or causes lethal mutagenesis upon incorporation into the virus RNA. In view of recent studies and discussion on favipiravir, in this mini review we aimed to summarize the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19. Twit Text FOAVip Favipiravir and COVID-19: A Simplified Summary ????Drug Res (Stuttg) http://www.kidney.de/pget.php?&tw=1&pmid=33176367 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33176367 #FOAvip English Wikipedia <ref>{{Cite pmid|33176367}}</ref> Favipiravir and COVID-19: A Simplified Summary #MMPMID33176367 Ghasemnejad-Berenji M; Pashapour S Drug Res (Stuttg) 2021[Mar]; 71 (3): 166-170 PMID33176367show ga A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan, China, at the end of 2019 and then spread rapidly all over the world. However, there are no specific antiviral therapies for COVID-19, using the agents which approved or in development for other viral infections is one of the potentially quickest ways to find treatment for this new viral infection. Favipiravir is an effective agent that acts as a nucleotide analog that selectively inhibits the viral RNA dependent RNA polymerase or causes lethal mutagenesis upon incorporation into the virus RNA. In view of recent studies and discussion on favipiravir, in this mini review we aimed to summarize the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19. |*COVID-19 Drug Treatment[MESH] |Amides/pharmacology/*therapeutic use[MESH] |Antiviral Agents/pharmacology/*therapeutic use[MESH] |COVID-19/virology[MESH] |Clinical Trials as Topic[MESH] |Coronavirus RNA-Dependent RNA Polymerase/*antagonists & inhibitors[MESH] |Humans[MESH] |Mutagenesis/drug effects[MESH] |Pyrazines/pharmacology/*therapeutic use[MESH] |RNA, Viral/drug effects/genetics[MESH] |SARS-CoV-2/*drug effects/enzymology/genetics[MESH]Favipiravir and COVID-19: A Simplified Summary (epmc).pdf DeepDyve Pubget Overpricing